Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function

Summary

To evaluate the pharmacokinetics and safety of Larotinib in subjects with mild and moderate hepatic function impairment and healthy subjects in a single-center, non-randomized, open, single-dose administration

Timeline

Start

2026-10-30

Primary completion

2026-12-30

Completion

2026-12-30

Drugs

Indications